Hepatocellular carcinoma
Conditions
Interventions
Preparation 1) DDPH for TAI 50 mg of DDPH powder are dissolved in 70 ml of saline, and the resulting solution is administered intra-arterially about 30 min using a mechanical infusion pump. 2) DDPH
Andre Guerget, Aulnay-sous-Bois, France). The DDPH-LPD suspension was prepared by mixing 50 mg of DDPH into 10 mL of LPD. The dosage of DDPH-LPD suspension was adjusted depending on the tumor size, nu
Nippon Kayaku, Tokyo, Japan) mixed with contrast medium.
Sponsors
Iwate Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Eligibility criteria were as follows: (1) Eastern Cooperative Oncology Group (ECOG) performance status of 0&#8211;2; (2) age over 20 years; (3) diagnosis of HCC based on imaging or histological findings; (4) no indication for surgical resection or local ablation therapy such as radiofrequency ablation (RFA) (5) bidimensionally measurable hepatic lesions; (6) adequate hepatic function (serum total bilirubin <3.0 mg/dl), and adequate renal function (serum creatinine <the upper normal limit); (7) no HCC treatment for 4 weeks before study entry.
Exclusion criteria
Exclusion criteria: Pregnancy women Patients who had allergy of cisplatin Patients who had severe disease except HCC.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy endpoint of the current study was the objective response rate. | — |
Countries
Japan
Outcome results
None listed